Generic Semaglutide Brands in India Complete List | MetaGO

Generic Semaglutide in India: Every Brand Available, Compared

Table of Contents

Quick Answer
Since the Indian semaglutide patent expired in March 2026, at least 20 brands from 12 Indian companies have publicly launched generic semaglutide. These include Sun Pharma (Noveltreat, Sematrinity), Dr Reddy’s (Obeda), Zydus (Semaglyn), and Glenmark (GLIPIQ).Every brand carries the same molecule. However, they differ in device, how the strength is labeled, and in approved use: type 2 diabetes, weight management, or both. The pens are not interchangeable, and dose markings and mechanics vary by brand, so any switch requires a new prescription and a demonstration. Every semaglutide brand is prescription-only and CDSCO-approved. 

Every Generic Semaglutide Brand in India

At least 12 Indian companies sell generic semaglutide in India under more than 20 brand names, all launched after 20 March 2026. The table groups every brand with a public launch statement or a verified pharmacy listing by company.

BrandCompanyStrengths statedDevice
ObedaDr Reddy’sPens: 2 mg, 4 mg; tablets: 3, 7, 14 mgDisposable multi-dose pen; tablets
SematrinitySun PharmaDiabetes strengths, not itemizedMulti-dose pen with dial
NoveltreatSun Pharma0.25, 0.5, 1, 1.7, 2.4 mgSingle-dose prefilled pen, hidden needle
Semaglyn, Mashema, AltermeZydus Lifesciences15 mg/3 mL cartridgeReusable pen
Semanext, LivariseLupin (made by Zydus)15 mg/3 mL cartridgeReusable pen
Sembolic, SemalixTorrentPens not itemized; tablets 3, 7, and 14 mgPens; tablets
Semasize, Obesema, HepaglideAlkemNot itemizedDisposable pen, cartridge pen, prefilled syringe
GLIPIQGlenmark2, 4, 8 mgMulti-dose vial; prefilled pen
Semanat, SemafullNatco2, 4, 8 mgMulti-dose vial; pen announced
SundaeEris (made by Natco)2, 4 mgMulti-dose vial; pen announced
UsemaUSV (with Dr Reddy’s)2, 4 mgPen
SemabestMSN LaboratoriesNot itemizedPrefilled pen
WyntideCorona RemediesNot itemizedPrefilled multi-dose pen

Generic semaglutide brands with a public launch in India, 21 March to 8 October 2026. Strengths as stated by each company. These names are listed for reference only, not as a recommendation.

You will notice five names deliberately missing from this table because they are not generics. Ozempic, Wegovy, and Rybelsus are Novo Nordisk’s originals, while Poviztra (sold by Emcure) and Extensior (sold by Abbott) are licenses second brands of Wegovy and Ozempic.

Many of the brands also share the same factory. Zydus makes what Lupin sells, Natco makes what Eris sells, and Torrent sources from Zydus, Dr Reddy’s, and MSN.

How the Generics Differ

While the packaging may differ, the molecule is identical across every box. However, the device, how the strength is written, the dose ladder, and the approved use vary by brand.

Strengths and dose steps

Every brand follows a ladder rather than a single dose. Semaglutide is start low and increases in steps (dose escalation), usually every four weeks, so the stomach has time to adjust. According to the STEP 1 and SUSTAIN 1 trials, weight-management dosing climbs from 0.25 mg per week to 2.4 mg, while diabetes dosing usually settles at 1 mg or 2 mg.

However, here’s one detail that confuses many first-time buyers. Indian generics label strength in two entirely different ways. For example, Sun Pharma’s Noveltreat labels each pen by the weekly dose it delivers. However, most diabetes brands label the pen by the total amount of drug inside it. So, a “4 mg” pen is not a 4 mg dose. 

Think of a one-liter milk packet and a glass. The packet tells you how much milk’s in it, not how much you drink in one sitting.

On the other hand, tablets operate on a different scale altogether. Generic tablets come in 3, 7, and 14 mg, far higher than any injection, because most of a swallowed dose never reaches the blood.

A 2018 study in Science Translational Medicine showed how an absorption helper (SNAC) lets a small amount of medicine cross the stomach lining right beside the dissolving tablet. But this finding does not imply that you can swap a 14 mg tablet for a 1 mg injection.

Pen devices: prefilled vs reusable

The generic semaglutide in India typically comes in five formats, and the format shapes daily use more than the brand name.

FormatHow it worksWhat it asks of the userBrands
Single-strength prefilled penOne fixed dose strength per penA new pen at every dose stepNoveltreat
Multi-dose disposable penA dial selects the dose; the pen is discarded when empty.Reading the dial correctlySematrinity, Obeda, Usema, Semasize, GLIPIQ pen
Reusable cartridge penThe pen body stays; only the cartridge changes.Loading a cartridge: one pen covers every step.Semaglyn, Livarise, Semasize Plus
Multi-dose vialEach dose is drawn up with a syringe.Measuring a small volume accuratelyGLIPIQ, Semanat, Sundae
Single-shot prefilled syringeOne dose per syringe, used onceNothing beyond the injection itselfAlkem (since June 2026)

Of these formats, vials are the most difficult. The vial format requires users to convert a dose written in milligrams into a volume on a syringe. Anyone prescribe a vial is better serve having a nurse or pharmacist guide the first draw in person than learning it from a video.

Approved indications

CDSCO approves a product for a particular use, and each brand follows that approval. For instance, Sun Pharma is the only company that sells the medications for the two uses under separate brand names. The table below mentions each brand and its approved use.

Approved use, as announcedBrands
Type 2 diabetesObeda (pens and tablets), Sematrinity, GLIPIQ, Semanat and Semafull, Torrent’s tablets
Chronic weight managementNoveltreat
BothSemaglyn, Mashema, Alterme (Zydus); Semasize, Obesema, Hepaglide (Alkem)
Not specified at launchSemanext, Livarise, Sundae, Usema, Semabest, Wyntide

No diabetes-only brand has been review for weight management, even though it has the same molecule. Whether a particular brand suits your situation is up to your doctor.

Indian doctors also judge eligibility differently from Western ones. India’s 2025 revised definition of obesity diagnoses obesity at a BMI above 23 and uses a waist of 90 cm in men and 80 cm in women as a marker of abdominal obesity. 

The need is not small. The national ICMR-INDIAB-17 survey found generalized obesity in 28.6% of adults and abdominal obesity in 39.5%: more than one in four adults and close to two in five.

Price per Month Compared

Two brands with the same molecule can cost very different amounts each month, and the medicine itself is rarely the reason. This section does not print prices, because they change with strength, pack, and pharmacy. Instead, it explains what drives the cost and how to calculate your own.

What moves the costHow it changes your monthly bill
The deviceA vial leaves the syringe and the measuring to you. A pen builds the dose, and a single-dose pen does that afresh every week. The more the device does for you, the more you pay.
The dose stepTreatment starts at the lowest dose and steps up. The first month is usually the least expensive month of the course, not a guide to the months after it.
The approved useWeight-management doses climb higher than diabetes doses, so the weight-management side of a brand usually costs more as the ladder rises.
Weeks per packA multi-dose pen, vial, or 15 mg cartridge lasts a different number of weeks at each dose. The same pack can be good value at one dose and poor value at another.
The extrasNeedles for some pens and syringes for vials may be sold separately.

The device is where most of the difference sits. Once the molecule went generic, the margin moved out of the medicine and into whatever delivers it.

Calculating your monthly cost takes five minutes at the pharmacy counter, and it is easier to do it week by week at first.

StepWhat to do
1Read the MRP printed on the pack your doctor has prescribed.
2Ask the pharmacist how many weekly doses that pack provides at your current dose.
3Divide the MRP by that number. That is your cost per week.
4Multiply by four for a month, and add needles or syringes if they are sold separately.
5Repeat at each dose step, because the figure changes as the dose climbs.

The same sum is the only fair way to compare two brands your doctor considers suitable. Put their weekly cost side by side at the same dose, rather than comparing one box to another.

Are Indian Generics Interchangeable

The simple answer is no. Indian generic semaglutide brands share a molecule, but India has no formal “interchangeable” designation, so a pharmacist should not swap one brand for another without your doctor agreeing.

There are three main reasons for this. Devices, manufacturing routes, and approved uses can differ, so a click that delivers 1 mg on one pen can mean something else on another. Some makers build the peptide chemically, others grow it in cells, and each route leaves its trace of impurities. So switching without consulting your doctor is not recommend.

Supply is the main reason switches happen. If a brand runs short mid-course, call the prescribing doctor before the next weekly dose. A gap of a week or more can change where the next dose should sit on the ladder, and the doctor must decide. Your doctor will usually keep you at an equivalent dose and supervise the first injection on the new device.

CDSCO Approval: What It Means

CDSCO approval means that the Central Drugs Standard Control Organization, head by the Drugs Controller General of India (DCGI), has review one specific product and allow it to be made and sold for one specific use. It is a product-by-product decision, not a license for the molecule.

Semaglutide still counts as a new drug in Indian law. Under the New Drugs and Clinical Trials Rules, 2019, a medicine retains that status for four years from approval, and copies within that window need expert committee review rather than a simple paperwork check.

Therefore, most companies collected clinical data and not just a lab report. Sun Pharma’s weight-management approval followed a Phase III trial in India, and Natco’s followed a clinical comparison study. Dr Reddy’s also ran a head-to-head Phase III study in 312 people and reported its product as non-inferior to the original for blood sugar control, with no anti-drug antibodies detected.

An antibody check is another vital step; our immune systems can sometimes react to a peptide medicine made through a different process. 

A drug reaches Indian pharmacies only after the regulator reviews the clinical data and is satisfy with the efficacy and safety for that use. No trial has ranked one generic against another, so no brand can honestly claim to be the “better one.”

Approval comes with limits too. Regulators warn companies against direct or disguised promotion of these medicines, and their expert committee has also recorded prescribing conditions, in one case limiting a product to endocrinologists. 

To check a pack, look for the Rx symbol, the manufacturer’s name and license number, and a batch number with an expiry date. Buy only from a licensed pharmacy with a valid prescription.

How to Choose Between Brands

The decision depends on you and your doctor. The brand matters less than how well you can use it. Here are five questions to help you focus your choice.

QuestionWhy it matters
Is this brand approved for my condition?Diabetes-only and weight-management brands carry different labels.
Which device can I use confidently every week?A missed or misdialled dose undoes more than any brand difference.
Does it cover my current and next dose step?Some ranges need a new pen at every step; others dial several doses from one device.
Can I store it properly at home and while traveling?Heat damages the peptide. Fridge space and travel plans count.
Is supply steady?A gap mid-course means an unplanned switch.

A device you dread will cost you more in skipped doses than what it saves at the counter. For someone with shaky hands or weak eyesight, a single-dose pen can be worth its higher price.

These medicines work best by the plate, not instead of it. In most Indian homes, that starts with the evening thali: an extra katori of dal, one roti fewer, and a walk after dinner.

Update Log

The Indian semaglutide market changes almost every month. This log records what changed and when, so you can judge how current the page is.

DateWhat changed
21 Mar 2026First generic launches after patent expiry: Sun Pharma, Dr Reddy’s, Zydus, Alkem, Glenmark, Torrent, Natco, Eris, USV, and Lupin.
15 Apr 2026MSN Laboratories launches Semabest in a prefilled pen.
20 May 2026Dr Reddy’s adds oral semaglutide tablets (3, 7, and 14 mg) under Obeda. Torrent’s Semalix tablets were already on sale.
9 Jul 2026Dr Reddy’s announces a temporary supply delay for certain batches after an ingredient quality finding; the company says safety is not affected.
Aug 2026The draft national semaglutide monograph is reported to be under preparation for the Indian Pharmacopoeia. Not yet in force.
23 Oct 2026Page published. Verified the brand table against company statements, trade reports, and pharmacy listings.
Next reviewNovember 2026.
Conclusion
Generic semaglutide in India now spans more than 20 brands, and they differ less in medicine and more in label, device, and approved use. Read the pack strength carefully, choose a device you can use confidently, and compare cost per weekly dose rather than per box. And start or switch any brand only under a doctor’s supervision.

Frequently Asked Questions

1. Which generic semaglutide brands are sold in India?

As of 8 October 2026, 20 brands from 12 companies had a public launch: Obeda (Dr Reddy’s), Sematrinity and Noveltreat (Sun Pharma), Semaglyn, Mashema and Alterme (Zydus), Semanext and Livarise (Lupin), Sembolic and Semalix (Torrent), Semasize, Obesema and Hepaglide (Alkem), GLIPIQ (Glenmark), Semanat and Semafull (Natco), Sundae (Eris), Usema (USV), Semabest (MSN), and Wyntide (Corona Remedies).

2. Are all Indian generics the same strength and dose?

No. They share the molecule but not the labeling. Noveltreat is labeled by weekly dose (0.25 mg to 2.4 mg), while most diabetes pens and vials are labeled by total contents (2, 4, or 8 mg), and you dial in or draw the weekly dose from them. Tablets come in 3, 7, and 14 mg and are not dose-equivalent to injections.

3. Which brand is cheapest per month?

No single brand is cheapest for everyone. Monthly cost depends on the device, your dose, and how many weeks one pack lasts at that dose. The cost increases as the dose increases. Divide the MRP printed on each pack by the number of weekly doses it provides at your prescribed dose, and ask your pharmacist to confirm.

4. Do the pen devices work the same way?

No. Some are single-dose pens designed for one use; some are multi-dose pens you can dial; some use replaceable cartridges, and vials need a syringe. Needles and cartridges are often made for their own devices. Switching brands requires a new prescription and a brief in-person demonstration of the new device.

5. How often is this list updated?

Every month. Each review checks company filings, CDSCO notices, and pharmacy listings with dates. The update log on this page records what changed. This version covers brands with a public launch record up to 8 October 2026, and the next review is due in November 2026.

Medical Disclaimer
This article is for general education and is not medical advice. It does not recommend, promote, or endorse any medicine or brand. Semaglutide is a prescription-only medicine in India and should be used only under the supervision of a qualified doctor who has assessed your health. Do not start, stop, switch, or change the dose of any medicine without consulting a doctor. Brand availability, strengths, and prices change; details here reflect publicly reported information up to 8 October 2026. 
  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  2. Sorli C, Harashima S, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260. doi:10.1016/S2213-8587(17)30013-X
  3. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
  4. Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-489. doi:10.1016/S2213-8587(23)00119-5
  5. Misra A, Vikram NK, Ghosh A, Ranjan P, Gulati S, et al. Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr. 2025;19(1):102989. doi:10.1016/j.dsx.2024.102989
Picture of Dr. Kaushal Patel

Dr. Kaushal Patel

MBBS, MD (Medicine), [Cardiologist Specialist in Diabetology & Obesity Management]